Results 1 to 10 of about 1,549,035 (266)

Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents

Clinical Epigenetics, 2019
Background Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) constitute a small KIT/PDGFRA-WT GIST subgroup featuring DNA methylation which, although pervasive, appears nevertheless not randomly distributed.
Riccardo Ricci, Maurizio Martini, Gloria Ravegnini, Tonia Cenci, Massimo Milione, Paola Lanza, Francesco Pierconti, Donatella Santini, Sabrina Angelini, Alberto Biondi, Fausto Rosa, Sergio Alfieri, Gennaro Clemente, Roberto Persiani, Alessandra Cassano, Maria A. Pantaleo, Luigi M. Larocca   +16 more
doaj   +1 more source

In Vivo Evidence of Melatonin’s Protective Role in Alkylating-Agent-Induced Pulmonary Toxicity: A Systematic Review

Antioxidants
Alkylating agents, historically employed as chemical warfare agents and currently used as chemotherapeutic drugs, are known to induce significant pulmonary toxicity. Current clinical interventions often fail to fully prevent or reverse these pathological
Emma Sola, Jose A. Morales-García, Francisco López-Muñoz, Eva Ramos, Alejandro Romero   +4 more
doaj   +1 more source

Therapy related acute myeloid leukemia with t(10:16): a rare entity

Hematology Reports, 2011
Treatment related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) are well known complications after chemotherapy for various hematologic and non-hematologic malignancies. Alkylating agents and Topoisomerase inhibitors are most widely
Guldeep K. Uppal, John Leighton, Deline Da Costa, Andrew Czulewicz, Irma E. Palazzo   +4 more
doaj   +1 more source

Chemoprotective effect of cysteamine against the induction of micronuclei by methyl methanesulfonate and cyclophosphamide

Genetics and Molecular Biology, 2005
Cysteamine or 2-mercaptoethylamine (MEA) is an aminothiol with a well-known radioprotective action. No specific information is available in the literature about the possible chemoprotective action of MEA against genotoxic chemical agents.
Renato Santos-Mello, Luiz Irineu Deimling, Claudio Lauer Júnior, Thaís Rieger de Carvalho   +3 more
doaj   +1 more source

O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy

Frontiers in Oncology, 2020
Chemoresistance has been a significant problem affecting the efficacy of drugs targeting tumors for decades. MGMT, known as O6-methylguanine-DNA methyltransferase, is a DNA repair enzyme that plays an important role in chemoresistance to alkylating ...
Wei Yu, Wei Yu, Lili Zhang, Lili Zhang, Qichun Wei, Qichun Wei, Anwen Shao   +6 more
doaj   +1 more source

Short story of antirheumatic therapy.VIII. The immunodepressants

Reumatismo, 2012
The use of immunosuppressive drugs in rheumatology is fairly recent, starting just after the Second World War with the introduction of the first alkylating agents in oncohematology.
P. Marson, G. Pasero
doaj   +1 more source

Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure

Case Reports in Oncological Medicine, 2018
SOS is a rare complication of stem cell transplantation and has significant morbidity and mortality. We present three cases of SOS and highlight underlying risk factors for its development, such as impaired clearance of alkylating agents (especially ...
Urvi A. Shah, Sengottuvel Viswanathan, Beamon Agarwal, Aditi Shastri, Ioannis Mantzaris, Murali Janakiram, Noah Kornblum, Ira Braunschweig, Amit Verma, Yang Shi, John Reinus, Olga Derman   +11 more
doaj   +1 more source

Differential response of biochemical parameters to EMS and MMS treatments and their dose effect relationship on chromosomes in induced diabetic mouse

Egyptian Journal of Medical Human Genetics, 2015
Aim: To study the effect of alkylating agents such as EMS and MMS on chromosomes and biochemical parameters in induced diabetic mouse. Methods: Chromosome preparations from bone marrow was made using the method of Evans et al.
B.B.D. Khalandar, V. Vasudev
doaj   +1 more source

Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report

Case Reports in Oncology, 2013
Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy.
Laura Van Ginderachter, Tony Cox, Ria Drijkoningen, Ruth Achten, Eric Joosens, Annelies Maes, Koen Theunissen, Jeroen Mebis   +7 more
doaj   +1 more source

The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights

Frontiers in Immunology
Osteosarcoma, the most aggressive primary malignant bone tumor, has stagnant therapeutic outcomes despite decades of standard MAP chemotherapy and surgery; 5-year overall survival (OS) is <30% for metastatic/recurrent cases.
Lifeng Ge, Tianhao Xu, Xiaodong Gu, Xuekang Pan, Tian Gao, Huigen Lu   +5 more
doaj   +1 more source